Device Trial Radar · NCT03969862
Validation Study of NOVEOS® System (HYCOR)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
536
Actual
Start
Dec 4, 2019
Primary completion
Mar 10, 2020
Study completion Mar 10, 2020
Sponsor
- Lead sponsor
- University Hospital, MontpellierAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hycor Biomedical
- First posted
- May 31, 2019
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Background : The NOVEOS® method is a chemiluminescent immunoassay used to provide quantitative detection of total IgE and allergen-specific IgE antibodies in human serum. The IgE antibody assay has an essential place in the diagnosis of mediated IgE allergies. This system could become an alternative to the techniques used today. NOVEOS® uses a quick and convenient method to give results concerning the patient's sensitization profile towards allergens. The volume required for the assays is 4 μl (against more than 100 μl for current techniques), which is particularly important in pediatric and geriatric populations where it may be more difficult to take larger samples. NOVEOS® also brings true autonomy. In fact, the incorporated reagents provide sufficient capacity for 8 hours of continuous testing. Objective: Validate the NOVEOS® system as an allergy diagnostic tool, by estimating the sensitivity and specificity of the NOVEOS® assays compared to the gold standard diagnostic represented by the clinical history and PT positive, for a panel of 20 allergens Methods: This is a validation study of a new immunoassay method (Système NOVEOS®). The study includes : * A preliminary phase to familiarize the team with the use of the NOVEOS® system. It is planned to analyze its technical characteristics: the precision, the sensitivity. Eight allergens will be tested, on a cohort of 136 patients * A validation study of the technique as a diagnostic tool for allergy (sensitivity and specificity compared to the gold standard represented by clinical history and positive PT) and comparison between the new technique and the ImmunoCap® system. Twenty allergens will be tested prospectively, each on 50 cases and 10 controls. A single patient may be both a case for an allergen and a witness for another. For rare allergies, the blood database of the Allergy Service will be used, and affected patients will be contacted to request their non-opposition.
Conditions
- Allergen-mediated IgE Allergy
Interventions
NOVEOS® systemDevice
The NOVEOS® System is a fully automated, high-throughput immunoassay platform that uses magnetic microbeads as a solid phase. This is a partially closed system that is primarily intended for the determination of specific IgE with NOVEOS® Hycor allergens. It has the CE mark.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity of the NOVEOS® assay compared to the gold standard diagnosis.Time frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Montpellier
Montpellier, Occitanie, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.